A Study of r-PA Treating Patients With Acute Ischemic Stroke(RAISE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1412 participants.

Also called NCT05295173

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,412 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05295173
Other papers using this trial's data
  • Efficacy and Safety of Reteplase Versus Alteplase in Acute Ischemic Stroke Based on Fibrinogen Levels: The RAISE Trial Subgroup Journal of the American Heart Association, 2026-05-19 DOI, PubMed 42089199, PMC13279563 In the PMC Open Access subset under CC BY-NC-ND.
  • Reteplase versus Alteplase for Acute Ischemic Stroke The New England journal of medicine, 2024-06-27 DOI, PubMed 38884332

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05295173. Randomized; no masking; primary purpose treatment. Start 2022-03-21 (actual); primary completion 2023-06-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of r-PA Treating Patients With Acute Ischemic Stroke(RAISE)
Condition
Acute Ischemic Stroke
Intervention (Drug)
Injection of recombinant human tissue plasminogen kinase derivatives
Intervention (Drug)
Recombinant human tissue plasminogen activator
Lead sponsor
Angde Biotech Pharmaceutical Co., Ltd. (class: industry)
Collaborator
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct05295173
Content hash
df18d88e15b6ad6d76463b96b5573beb6ac05a7179cdc446db7dd7c553319285